Tumor mutational burden (TMB) in real-world patients with pancreatic ductal adenocarcinoma (PDAC): Differences in genomic alterations (GA) and predictive value for immune checkpoint inhibitor (ICI) effectiveness

被引：0
|
作者：
Mahipal, Amit
Quintanilha, Julia C. F.
Graf, Ryon
Storandt, Michael H.
Keller, Rachel B.
Li, Gerald
Ross, Jeffrey S.
Huang, Richard S. P.
Schrock, Alexa Betzig
Oxnard, Geoffrey R.
Chakrabarti, Sakti
机构：
[1] Case Western Reserve Univ, Seidman Canc Ctr, Cleveland, OH USA
[2] Fdn Med Inc, Boston, MA USA
[3] Mayo Clin, Rochester, MN USA
[4] Fdn Med Inc, Cambridge, MA USA
[5] Fdn Med Inc, Morrisville, NC USA
[6] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4146
引用
收藏
页数：1
相关论文
共 18 条
  • [1] Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness
    Quintanilha, Julia C. F.
    Storandt, Michael H.
    Graf, Ryon P.
    Li, Gerald
    Keller, Rachel
    Lin, Douglas I.
    Ross, Jeffrey S.
    Huang, Richard S. P.
    Schrock, Alexa B.
    Oxnard, Geoffrey R.
    Chakrabarti, Sakti
    Mahipal, Amit
    JCO PRECISION ONCOLOGY, 2023, 7
  • [2] Microsatellite instability (MSI), mismatch repair (MMR), and tumor mutational burden (TMB) as predictive biomarkers for immune checkpoint inhibitor (ICI) effectiveness in real-world patients with metastatic colorectal cancer (mCRC).
    Ellis, Haley
    Klempner, Samuel J.
    Quintanilha, Julia C. F. C. F.
    Myer, Parvathi
    Lin, Douglas I.
    Panarelli, Nicole
    Fisher, Virginia
    Li, Gerald
    Huang, Richard S. P.
    Ross, Jeffrey S.
    Oxnard, Geoffrey R.
    Graf, Ryon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 46 - 46
  • [3] Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer
    Graf, Ryon P.
    Fisher, Virginia
    Creeden, James
    Schrock, Alexa B.
    Ross, Jeffrey S.
    Nimeiri, Halla
    Oxnard, Geoffrey R.
    Klempner, Samuel J.
    CANCER RESEARCH COMMUNICATIONS, 2022, 2 (09): : 1037 - 1048
  • [4] Real-world pan-cancer landscape of frameshift mutations (FSM) and their role in predicting responses to immune checkpoint inhibitors (ICI) in patients (pts) with tumors with low tumor mutational burden (TMB).
    Florou, Vaia
    Floudas, Charalampos S.
    Maoz, Asaf
    Naqash, Abdul Rafeh
    Hildebrand, Gregory
    Sokol, Ethan
    Frampton, Garrett M.
    Puri, Sonam
    Swami, Umang
    Wilky, Breelyn A.
    Hosein, Peter Joel
    Trent, Jonathan C.
    Lopes, Gilberto
    Park, Wungki
    Garrido-Laguna, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Role of tumor mutational burden (TMB) and microsatellite instability (MSI) in patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitor (ICI)
    Bakaloudi, Dimitra Rafailia
    Talukder, Rafee
    Makrakis, Dimitrios
    Diamantopoulos, Leonidas Nikolaos
    Patgunarajah, Ubenthira
    Thomas, Vinay Mathew
    Jindal, Tanya
    Brown, Jason R.
    Miletic, Marija
    Johnson, Jeffrey
    Hui, Gavin
    Buznego, Lucia Alonso
    Morales-Barrera, Rafael
    Castaneda, David Humberto Marmolejo
    Nguyen, Charles B.
    Barata, Pedro C.
    Stewart, Tyler F.
    Gupta, Shilpa
    Grivas, Petros
    Khaki, Ali Raza
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 654 - 654
  • [6] Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma
    Andrews, Miles C.
    Li, Gerald
    Graf, Ryon P.
    Fisher, Virginia A.
    Mitchell, Jerry
    Aboosaiedi, Ali
    O'Rourke, Harriet
    Shackleton, Mark
    Iddawela, Mahesh
    Oxnard, Geoffrey R.
    Huang, Richard S. P.
    JCO PRECISION ONCOLOGY, 2024, 8
  • [7] Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma
    Andrews, Miles C.
    Li, Gerald
    Graf, Ryon P.
    Fisher, Virginia A.
    Mitchell, Jerry
    Aboosaiedi, Ali
    O'Rourke, Harriet
    Shackleton, Mark
    Iddawela, Mahesh
    Oxnard, Geoffrey R.
    Huang, Richard S. P.
    JCO PRECISION ONCOLOGY, 2024, 8
  • [8] Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-naive and -experienced patients with metastatic melanoma treated with lifileucel, a tumorinfiltrating lymphocyte (TIL) cell therapy.
    Kluger, Harriet M.
    Sarnaik, Amod
    Chesney, Jason Alan
    Lewis, Karl D.
    Weber, Jeffrey S.
    Gogas, Helen
    In, Gino Kim
    Terheyden, Patrick Andres Maximilian
    Lee, Sylvia
    Jagasia, Madan H.
    Masteller, Emma
    Qi, Rongsu
    Gontcharova, Viktoria
    Shi, Wen
    Fiaz, Rana
    Sulur, Giri
    Wu, Renee Xiao
    Chen, Guang
    Thomas, Sajeve Samuel
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Biomarkers of Chinese advanced cancer patients based on real-world data: Actionable genomic alterations and tumor mutational burden.
    Wang, HaiTao
    Wang, Huina
    Guo, Rongyun
    Li, Mingwei
    Zhang, Yanrui
    Lou, Feng
    Cao, Shanbo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus chemotherapy benefit in first-line metastatic urothelial carcinoma: A real-world study.
    Gupta, Shilpa
    Huang, Richard S. P.
    Stanke, Jennifer
    Hamdani, Omar
    Gjoerup, Ole
    Alexander, Brian Michael
    Levy, Mia Alyce
    Oxnard, Geoffrey R.
    Graf, Ryon
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12